PMVP · PMV Pharmaceuticals, Inc.
$1.22
-0.02 (-1.61%)
At close · Aug 28
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has determined that the Company's current available cash, cash equivalents and marketable securities may not be sufficient to fund its planned operations for at least one year from the date of this Quarterly Report, and there is substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$65.49M
Shares
53.46M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$77.74M
-32.4%
FY2025
Diluted EPS
-$1.48
-29.8%
FY2025
Operating Cash Flow
-$73.58M
-43.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $4.48M | $6.34M | $10.66M | $11.17M | $3.63M | $449K | $651K | $1.3M | $1.34M | |
| $64.04M | $69.88M | $58.53M | $55.89M | $51.99M | $36.49M | $23.93M | $20.76M | $13.85M | |
| $15.62M | $16.33M | $26.92M | $24.25M | $25.05M | $21.8M | $11.01M | $5.88M | $5.04M | |
| $79.66M | $86.21M | $85.45M | $80.13M | $77.04M | $58.29M | $34.94M | $26.64M | $18.89M | |
| -$79.66M | -$86.21M | -$85.45M | -$80.13M | -$77.04M | -$58.29M | -$34.94M | -$26.64M | -$18.89M | |
| $4.47M | $6.29M | $10.64M | $11.17M | $3.71M | $470K | $508K | $1.29M | $1.36M | |
| -$75.2M | -$79.91M | -$74.81M | -$68.96M | -$73.33M | -$57.82M | -$34.43M | -$25.34M | -$17.54M | |
| — | -$2.17M | -$16.1M | $2000 | -$9000 | $23K | $6000 | $8000 | $3000 | |
| -$75.22M | -$77.74M | -$58.71M | -$68.96M | -$73.32M | -$57.85M | -$34.44M | -$25.35M | -$17.54M | |
| -$75.32M | -$77.8M | -$58.79M | -$68.29M | -$73.68M | -$57.92M | -$34.44M | -$25.34M | -$17.49M | |
| USD/shares | -$1.41 | -$1.48 | -$1.14 | -$1.44 | -$1.61 | -$1.28 | -$2.40 | — | — |
| USD/shares | -$1.41 | -$1.48 | -$1.14 | -$1.44 | -$1.61 | -$1.28 | -$2.40 | — | — |
| shares | — | 52.54M | 51.58M | 48.01M | 45.59M | 45.14M | 14.36M | 3.04M | 3.01M |
| shares | — | 52.54M | 51.58M | 48.01M | 45.59M | 45.14M | 14.36M | 3.04M | 3.01M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.91×
EV/EBIT
—
Peer median 12.63×
P/E (TTM)
—
Peer median 8.50×
Peer medians compare against the 280 similar-size Biotechnology companies (of 508 listed).
Key facts
CIK
1699382
CUSIP
69353Y103
13F (30d)
63 filings
63 filers
Visit website
Investor relations